Oral Anticoagulation in Patients with End Stage Renal Disease and Atrial Fibrillation: The Need to Evaluate Net Clinical Effect

Circulation. 2016 Jan 19;133(3):242-4. doi: 10.1161/CIRCULATIONAHA.115.020378. Epub 2015 Dec 17.

Authors

Manesh R Patel¹, Jonathan P Piccini²

Affiliations

¹ From Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (M.R.P., J.P.P.); and Duke Center for Atrial Fibrillation, Duke University, Durham, NC (J.P.P.).
² From Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (M.R.P., J.P.P.); and Duke Center for Atrial Fibrillation, Duke University, Durham, NC (J.P.P.). jonathan.piccini@duke.edu.

PMID: 26680240
DOI: 10.1161/CIRCULATIONAHA.115.020378

No abstract available

Keywords: Editorials; anticoagulants; atrial fibrillation; clinical trial; kidney diseases.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Atrial Fibrillation / epidemiology*
Atrial Fibrillation / mortality*
Female
Hospital Mortality / trends*
Humans
Male
Renal Dialysis / mortality*
Stroke / epidemiology*
Stroke / mortality*